

FORM PTO-1449

SERIAL NO.

09/708,276

CASE NO.

8642/94

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

FILING DATE

November 7, 2000

GROUP ART UNIT

1636

(use several sheets if necessary)

APPLICANT(S):

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
<i>JS</i>	A1	5,863,904	1/26/99	Nabel et al.	514/44	
<i>JS</i>	A2	5,672,508	09/30/97	Gyuris et al.	435/320.1	
	A3					
	A4					
	A5					
	A6					
	A7					
	A8					
	A9					
	A10					
	A11					
	A12					
	A13					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
<i>JS</i>	A14	WO 95/18824	7-13-95	WO	514/44	
<i>JS</i>	A15	WO 96/25507	8-22-96	WO	435/320.1	
<i>JS</i>	A16	WO 9602140A1	02/1996	PCT		
	A17					
	A18					

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
<i>JS</i>	A19	PCT Notification of Transmission of The International Search Report or the Declaration (8 pages), Mailed 1/14/99.
<i>JS</i>	A20	Chen et al., "Downregulation of Cyclin-dependent Kinase 2 Activity and Cyclin A Promoter Activity in Vascular Smooth Muscle Cells by p27 ^{KIP1} , an Inhibitor of Neointima Formation in the Rat Carotid Artery," pp. 2234-2341, J. Clin. Invest. 99 (10) 1997.
<i>JS</i>	A21	Toyoshima et al., "p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21," Cell, Vol. 78, 7/15/94, pp. 67-74. XXXX
<i>JS</i>	A22	Tanner et al., "Expression of Cyclin-Dependent Kinase Inhibitors in Vascular Disease," pp. 396-403, Circ. Res. 1998; Vol. 82.
<i>JS</i>	A23	Tanner et al., "Gene Transfer of p27 ^{KIP2} and p21 ^{CIP1} Cyclin-Dependent Kinase Inhibitors, But Not p16 ^{INK} , Negatively Regulate VSMC Proliferation Through Differential Effects on Kinase Activity," Circulation Vol. 96(8): SUPPL. Pg. I5 10/97.

EXAMINER

W. H. Smith

DATE CONSIDERED

3/16/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

FORM PTO-1449	SERIAL NO. 09/708,276	CASE NO. 8642/94
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 7, 2000	GROUP ART UNIT 636
(use several sheets if necessary)	APPLICANT(S): JAN 29 2001	

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
<i>AS</i>	A24	Braun-Dullaues et al., "Regulation of Vascular Smooth Muscle Cell Proliferation by the Cyclin-Dependent Kinase Inhibitor p27 ^{KIP1} ", one page J. Invest. Med., Vol. 45(3) p. 224A 3/97.
<i>AS</i>	A25	Hideo Toyoshima and Tony Hunter, "p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21", Cell, Vol. 78, pp. 67-74, July 15, 1994.
<i>AS</i>	A26	Kornelia Polyak et al., "Cloning of p27 ^{KIP1} , a Cyclin-Dependent Kinase Inhibitor and a Potential Mediator of Extracellular Antimitogenic Signals", Cell, Vol. 78, pp. 59-66, July 15, 1994.
<i>AS</i>	A27	Steve Coats et al., "Requirement of p 27 ^{KIP1} for Restriction Point Control of the Fibroblast Cell Cycle", Science, Vol. 272, May 10, 1996, pp. 877-880.
<i>AS</i>	A28	Koyama et al. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors, Cell, Vol. 87, 1069-1078, December 13, 1996.

EXAMINER <i>William Sanders</i>	DATE CONSIDERED <i>3/16/02</i>
------------------------------------	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant